Showing results (2171-2180 of 2,195) with videos related to
Sort By:
Pageof 220
Nature Communications|December 19, 2019
Discovery of a chemical probe for PRDM9Abdellah Allali-Hassani, Magdalena M Szewczyk, Danton Ivanochko, et al.JAMA|November 3, 2024
A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical TrialWilliam J Heerman, Russell L Rothman, Lee M Sanders, et al.Journal of Medicinal Chemistry|September 24, 2015
Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer InhibitorsIzzat T Raheem, Abbas M Walji, Daniel Klein, et al.Genome Biology|December 31, 2015
KIAA0556 is a novel ciliary basal body component mutated in Joubert syndromeAnna A W M Sanders, Erik de Vrieze, Anas M Alazami, et al.Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.Neurogastroenterology and Motility|April 14, 2026
International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the DiseasePascal De Santa Barbara, Isabella Ceccherini, Robert O Heuckeroth, et al.Vaccine: X|October 24, 2024
A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvementsA J M Pluijmaekers, A Steens, H Houweling, et al.The Lancet. Neurology|April 22, 2024
Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): an international, double-blind, randomised, phase 2 trialNawaf Yassi, Henry Zhao, Leonid Churilov, et al.Journal of Medicinal Chemistry|February 7, 2003
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridinesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.Pageof 220